Send to

Choose Destination
Mol Autism. 2019 May 22;10:23. doi: 10.1186/s13229-019-0277-1. eCollection 2019.

Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes.

Author information

1Department of Neuroscience and the ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus MC University Medical Center, 3015 CN Rotterdam, The Netherlands.
2Neuroscience Center, Department of Cell Biology and Physiology, and Carolina Institute for Developmental Disabilities, University of North Carolina, Chapel Hill, NC USA.



Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by mutations affecting UBE3A gene expression. Previous studies in mice revealed distinct critical periods during neurodevelopment in which reactivation of Ube3a gene expression can prevent the onset of behavioral deficits. Whether UBE3A is required for brain function throughout life is unknown. Here, we address the importance of maintaining UBE3A expression after normal brain development.


Using a conditional mouse, we deleted the Ube3a gene at three ages spanning brain maturation. We assessed the consequences of Ube3a gene deletion by testing the mice in behavioral tasks previously shown to produce robust phenotypes in AS model mice. Early embryonic deletion of Ube3a recapitulated all behavioral deficits of AS mice. In contrast, Ube3a gene deletion at 3 or 12 weeks of age did not have a significant effect on most behavioral tasks and did not increase seizure sensitivity.


Taken together, these results emphasize that UBE3A critically impacts early brain development, but plays a more limited role in adulthood. Our findings provide important considerations for upcoming clinical trials in which UBE3A gene expression is reactivated and suggest that even transient UBE3A reinstatement during a critical window of early development is likely to prevent most adverse Angelman syndrome phenotypes. However, sustained UBE3A expression into adulthood is probably needed for optimal clinical benefit.


Angelman syndrome; Autism spectrum disorder; Mouse model; Phenotype; Seizure; Ube3a

Conflict of interest statement

Competing interestsY.E., B.D.P and M.C.J. have received money from pharmaceutical companies for consultation and/or drug testing studies regarding Angelman syndrome. The other authors declare that they have no competing interests.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center